Sienna's long-serving CEO steps down
Sienna Cancer Diagnostics has announced the resignation of CEO Dr Kerry Hegarty after 10 years at the helm.
The company has commenced a global search for a replacement, and Hegarty plans to stay on in a support capacity until a new chief is found.
Sienna Chairman Dr Geoff Cumming said Hegarty’s resignation serves as part of a long-term strategic transformation plan for the company.
“Over the past 12 months, Kerry and the board have been assessing the needs of the company as it embarks on its next chapter, including leadership and management needs for the next 2-3 years,” he said.
“As part of this process, the board and Kerry have agreed that now is an opportune time to attract a new and outstanding CEO to a transformed Sienna to lead the company into a new phase in its history, and allow Kerry to pursue other opportunities after many years of service.”
The move comes the same month Sienna secured its first revenue-generating deal for its telomerase detection technology based on Anti-hTERT antibody SCD-A7.
The company also recently completed a $2.1 million capital raising to help fund SCD-A7 development.
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
